Nov 16, 2026  ·  1 min read

Oyster raises $60 million for an experimental tau-targeting pill

A pill designed to clear a protein linked to Alzheimer’s has to get through the gut and into the brain. Oyster Therapeutics, a London drug development startup, has raised $60 million to advance an experimental treatment for tau, a protein that can accumulate in an unhealthy form in the brain.

Oyster’s chief executive says the drug is designed to split into smaller pieces that can cross biological barriers. Inside a cell, the pieces reassemble and direct the cell’s own disposal machinery to break down the target protein. The work is still at the preclinical stage. The company aims to bring the drug into human studies and has yet to give a timeline.

Source  ·  MedCity News ↗ Brain-Focused Startup Oyster Gets $60M to Beat the Size Problem for Small Molecule Degraders Oyster Therapeutics’ lead program penetrates the brain to degrade pathological tau associated with Alzheimer’s disease. Eli Lilly, maker of the…
  1. Nov 17Helus says its psychedelic pill beat placebo in a depression trial
  2. Nov 17Anthropic adds text watermarking to four Claude 4 models
  3. Nov 17HHS finalizes HIPAA changes: 15-day record access and health app transfers
  4. Nov 17FBI warns attackers are using the Artex AI hacking tool against companies
  5. Nov 16OpenAI lets its AI helpers complete your purchases

This is our sketchbook.

Two stoneware cups turned towards each other, as if in conversation

Got a good project?
Let’s work on it together.

Let’s talk →

info@ndot.io · New Jersey · Budapest · Biel